Tremelimumab (Imjudo)
Immunotherapy · Approved since 2022
Description
Tremelimumab is a fully human monoclonal antibody that targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) for the treatment of various solid tumors including colorectal cancer. This immunotherapy agent works by blocking inhibitory signals that prevent T-cell activation, thereby enhancing the body's immune response against cancer cells. In colorectal cancer treatment, tremelimumab is primarily used in combination with other agents such as durvalumab or cabozantinib, particularly in patients with microsatellite instability-high (MSI-H) tumors or specific molecular profiles including KRAS mutations.
Mechanism of Action
Tremelimumab binds to CTLA-4 receptors on T-cells, blocking the interaction between CTLA-4 and its ligands CD80 and CD86 on antigen-presenting cells. This blockade prevents the inhibitory signals that normally downregulate T-cell responses, leading to enhanced T-cell proliferation, activation, and anti-tumor immune activity.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Imjudo |
| Category | Immunotherapy |
 Status | FDA Approved |
 EMA Status | Not submitted to EMA |
 Spain Access | Not funded |
| Administration | IV |
| Year Approved | 2022 |
| Clinical Trials | 13 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.